| INTRODUCTION
Cardiac contractility modulation (CCM) is an electric device therapy that applies a nonactivating electrical impulse to the cardiac muscle during the absolute refractory period. 1 Indications for CCM include patients with reduced left ventricular ejection fraction (LVEF) and normal or slightly prolonged QRS duration, thus filling a therapeutic gap among the two-thirds of patients with heart failure (HF) who do not meet criteria for cardiac resynchronization therapy. 2, 3 Two prospective, randomized, multicenter studies have demonstrated significant improvements of New York Heart Association (NYHA) functional class, quality of life indexed by Minnesota Living with Heart Failure Questionnaire (MLWHFQ), and peak oxygen uptake during cardiopulmonary exercise testing in patients with symptomatic HF with reduced LVEF (HFrEF). [4] [5] [6] Although current data show improvements in symptoms and functional cardiopulmonary capacity, data on cardiovascular outcome are limited. Randomized controlled trials were not powered to detect statistically significant changes of cardiovascular mortality. 4, 5 A recent metaanalysis of published data found that CCM did not lower the risk of severe cardiovascular adverse events 7 ; nevertheless, retrospective observations suggest that mortality rates in patients treated with CCM, especially in those with normal QRS and with moderate disease stage, were lower than estimated by the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) model, by the Seattle Heart Failure Model (SHFM) model risk scores, or by a control group. [8] [9] [10] Recently, in the European Society of Cardiology (ESC) Guidelines on Acute and Chronic Heart Failure (2016), it was stated that CCM may be considered in selected patients with HF. 3 Because many patients receiving CCM have an LVEF ≤35%, an implantable cardioverter-defibrillator (ICD) is also indicated. In most of these cases, a separate implantation procedure is performed using intracardiac defibrillation leads and a separate implantable pulse generator, as no device currently combines CCM and ICD capabilities into a single device. As a result, CCM has been extensively studied in combination with intracardiac ICDs, revealing little interference between devices. However, the need for 2 devices, both with intracardiac leads, poses the risk of additional adverse events because the cumulative risk of electrode complications, such as systemic infections or thrombosis of central venous lines, increases with the number of implanted intracardiac leads.
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The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed as an alternative to the transvenous ICD without the need to implant transvenous leads. 12, 13 Its safety and effectiveness have been established, 14, 15 and the therapy has been included in current guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. 15, 16 In this present study, we analyzed the long-term clinical outcome of patients in whom both CCM and S-ICD were implanted. One of these leads is placed into the right atrium to detect the electrical activity as part of the algorithm for timing CCM delivery. CCM signal delivery occurs through the remaining 2 leads, positioned at the ventricular septum, after electrical activity is sensed in those leads. Active CCM treatment is typically programmed for 5 or 7 segments of 1 hour spread equally throughout the day.
| METHODS

| Patients
| S-ICD device description, implantation procedure, and device testing
The S-ICD system (Emblem; Boston Scientific, Marlborough, MA) and its implantation procedure have been described in detail. 
| Combining CCM and S-ICD
Three tests were performed upon insertion of the second device (either CCM or S-ICD) to exclude device interactions (Table 1) .
| Statistical analysis
Changes in each tested parameter were calculated for each patient comparing baseline to last follow-up visit. Data are reported as mean AE SD, and the t test was used for the univariate analysis.
3 | RESULTS
| Patient population
Baseline characteristics of the 20 CCM patients are given in Table 2 .
Mean age at CCM implant was 54.3 AE 11.5 years, and mean baseline LVEF was 24.4% AE 8.1%. Thirty-five percent of patients had ischemic cardiomyopathy.
In the course of their treatment all 20 patients received an S-ICD (Figure, A). In 14 patients, the S-ICD was the first implanted ICD device.
Thirteen of these 14 patients had a primary preventive ICD indication because LVEF was ≤35% for ≥3 months of optimal medical treatment.
One of these 14 patients had a secondary preventive ICD indication because he had a history of life-threatening sustained ventricular tachyarrhythmias in addition to LVEF ≤35%. These 14 patients received their S-ICDs before CCM implantation.
In 6 patients, a formerly implanted transvenous ICD was replaced by an S-ICD due to ICD lead defects. In 3 of these 6 patients, the first transvenous device was implanted for primary prevention and in the other 3 patients for secondary prevention.
Taken together, 80% of the study subjects underwent implantation of their first ICD for primary prevention and 20% for secondary prevention ( Table 2 ).
| Operation results
S-ICD and CCM implantations were successfully performed in all patients. Program S-ICD vector with the clearest result as selected sensing vector.
In case CCM is implanted after S-ICD, repositioning of CCM leads is possible during the implantation procedure to a location where the CCM signal shows fewer artifacts on the S-ICD sensing vectors.
Test 2: Intraoperative S-ICD Testing
Turn CCM signal delivery to "on" and induce VF.
CCM device contains a built-in algorithm that inhibits delivery of a CCM signal when irregular electrical activity is detected (such as premature atrial or ventricular complexes or sensing defects). This is designed to eliminate the possibility of CCM signal delivery during a T-wave.
When CCM detects ventricular arrhythmias, CCM signal delivery ceases.
S-ICD can properly recognize the arrhythmia and VF is terminated through ICD shock delivery.
Test 3: Postoperative Bicycle Ergometer Testing and Provocation Maneuvers
Turn CCM signal delivery to "on" and monitor all 3 sensing configurations of S-ICD.
Perform bicycle ergometer testing.
Perform provocation maneuvers (eg, aggregate manipulation, physical maneuvers, standing and supine posture).
Select sensing vector with the clearest signal, avoiding double counting or oversensing as well as noise that was produced by the CCM device.
Abbreviations: CCM, cardiac contractility modulation; ICD, implantable cardioverter-defibrillator; S-ICD, subcutaneous implantable cardioverterdefibrillator; VF, ventricular fibrillation. 
| Efficacy of CCM therapy
The mean duration of follow-up from CCM implantation was 34.3 AE 30.6 months (range, 7-94 months; median, 19 months).
There were significant improvements of NYHA class as well as MLWHFQ (Table 3) . LVEF also improved significantly, by 6.5%, and there was a trend toward a decrease in left ventricular end-diastolic diameter. Additionally, there were significant decreases of left ventricular end-systolic diameter, and left ventricular end-diastolic and end-systolic volumes. There were no significant changes seen in Nterminal pro brain natriuretic peptide or creatinine levels. Furthermore, QRS duration remained unchanged.
| Arrhythmias
Mean follow-up after dual device implantation was 22.0 AE 15.3 months (range, 5-61 months; median, 17 months). During this time, 3 patients experienced a total of 6 episodes of sustained VT at a mean follow-up of 7.2 AE 2.5 months with both devices active. Each episode was adequately treated with a single ICD shock. Patients' electrophysiological characteristics are described in Table 4 .
One patient (male, age 75 years, ischemic cardiomyopathy) received an inappropriate shock (see Supporting Information, Figure S1 , in the online version of this article). The patient had nonsustained VT for 11 seconds that was then followed by a phase of T-wave oversensing for 15 seconds. The T-wave oversensing led to the inappropriate shock. During the inappropriate shock event, CCM therapy was in an "off" phase, and therefore the inappropriate shock is unrelated to CCM. The patient received antiarrhythmic therapy with amiodarone and had no further ventricular tachyarrhythmias. Abbreviations: DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; S-ICD, subcutaneous implantable cardioverter-defibrillator; VT, ventricular tachycardia.
During the 22 months of follow-up with both devices active, none of the 20 patients had syncope. 
| Survival
| DISCUSSION
The major new finding from this study is that combination of CCM with S-ICD in patients with an indication for both is feasible and that it was safe and successful in this study cohort during long-term follow-up. The benefit of CCM therapy, as demonstrated by improvements of NYHA class, quality-of-life scores, and echocardiographic parameters, seems consistent with prior publications in larger populations. 5, 8, 19 Recent retrospective single-center observational studies have suggested prolonged survival of HF patients treated with CCM therapy. [8] [9] [10] In most of these studies, patients receiving CCM therapy had LVEF ≤35%; therefore, they also had ICD devices with intracar- In this study, we present the first long-term results of combined CCM and S-ICD devices. Using our established algorithm, the chances for detrimental crosstalk between CCM and S-ICD can be The new-generation Optimizer, the Optimizer Smart, includes an algorithm that does not require the implantation of an atrial lead (keeping the 2 ventricular leads only), thereby further simplifying the implantation procedure. The new mode also allows the delivery of CCM therapy in patients with permanent atrial fibrillation, which was considered a contraindication for the prior-generation Optimizer device. 21 In a recent study, it was demonstrated that efficacy and safety of CCM were similar when the signal was delivered through either 1 or 2 ventricular leads. 22 These results support the potential future use of a single ventricular lead for delivery of CCM, further reducing device implantation-associated risk.
| Study limitations
This study presents experience with the combination of CCM and S-ICD in a small cohort of patients from a single site. It presents limited data on clinical outcome in a nonrandomized, noncontrolled manner.
Further multicenter studies are needed to evaluate the long-term impact of combining these 2 technologies in support of patients with HFrEF and LVEF ≤35%, who comprise a large segment of the chronic HF population.
| CONCLUSION
S-ICD and CCM can be successfully combined to work efficaciously and safely in HFrEF patients who do not require cardiac pacing. A careful intraprocedural crosstalk test and postoperative exercise testing with both devices activated is recommended to identify and abate any functional interactions between the 2 devices.
With the long-term follow-up, it can be concluded that S-ICD therapy and CCM therapy can be safely used together, thereby decreasing risk by reducing the number of intracardiac leads implanted. A future device that combines CCM and ICD functions is desirable.
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